In a recent study comparing transcriptional and clinical data from three independent cohorts of breast cancer patients treated with taxane-based chemotherapy, we identified ATIP3—the major product of microtubule-associated tumor suppressor gene MTUS1—as a new predictive biomarker of tumor response to chemotherapy13. This evidence concerns the gene MTUS1 and breast carcinoma.